Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY 4.0Oncotarget

Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR

  • Wafik S. El-Deiry1,2,3
  • Sadakatsu Ikeda4
  • Shai Magidi1
  • Catherine Bresson1
  • Hikmat Abdel-Razeq5
  • Anthony Joshua6
  • Alberto Hernando-Calvo7
  • Arjun Oberoi7
  • Zhihuang Hu8
  • Tobias Meissner9
  • Rachel Elsey9
  • Amal Al-Omari5
2 more authors
  • Fanny Wunder1
  • Razelle Kurzrock1,10,3
10 affiliations
  1. 1Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France
  2. 2Legorreta Cancer Center at Brown University, Providence, RI 02912, USA
  3. 3These authors contributed equally to this work
  4. 4Institute of Science Tokyo Hospital, Tokyo 113-8510, Japan
  5. 5King Hussein Cancer Center, Amman 11941, Jordan
  6. 6The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia
  7. 7Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona 08035, Spain
  8. 8Fudan University Shanghai Cancer Center, Shanghai 200032, China
  9. 9Avera Cancer Institute, Sioux Falls, SD 57105, USA
  10. 10Medical College of Wisconsin, Milwaukee, WI 53226, USA
Read full textDOICite

Abstract

The WIN Consortium International Molecular Tumor Board brings together precision oncology experts from 18 organizations in 13 countries across four continents and provides discussion for patients with cancer across the world. This case report details the medical journey of a 55-year-old man diagnosed with high-grade glioblastoma (GBM), characterized by amplifications of MDM2 and EGFR, alongside other critical genomic alterations, including a CDKN2A frameshift mutation. Despite the aggressive nature of GBM, the patient was in remission following a combination of radiotherapy and chemotherapy, surgery and participation in a phase II clinical trial (PI3K/mTOR inhibitor) combined with ketogenic diet and metformin. However, the patient was also considering personalized neoantigen vaccine therapy targeting tumor-specific mutated peptides as part of his treatment strategy.

This case underscores the immense complexity of treating GBM. Next generation sequencing showed MDM2 amplification, which hinders the tumor-suppressive functions of p53, and EGFR amplification, which promotes oncogenic signaling. The experts highlighted various therapeutic options discussed in the event of relapse: EGFR inhibitors, various MDM2 inhibitors, and personalized combination therapies targeting both EGFR and CDK4/6. Additionally, the Molecular Tumor Board discussed the reported risk of resistance or hyper-progression with immune checkpoint blockade in the presence of EGFR and MDM2 alterations. Innovative approaches such as combining MDM2 and EGFR inhibitors with immunotherapy, as well as the use of teserpaturev, a genetically engineered herpes simplex virus were addressed. This case emphasizes the importance of personalized treatment strategies for GBM and the need for ongoing clinical research to explore novel therapeutic options.

Related

  1. Glioblastoma, IDH-wildtype, with spontaneous transdural and calvarial invasion: a case report and literature review
    Jianhang Lin, Jiayi Lin, Jiana Zhang +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment
    Joaquin Fiallo Arroyo, Jose E. Leon-Rojas
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. A logistic paradigm to predict molecular glioblastoma on clinical MRI
    Yousif Aldabbagh, Faheem Bhatti, Nitin Menon +7
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Molecular glue degraders of CK1α remodel lysosomes and limit ferroptosis in glioblastoma stem-like cells
    J. Jardine, M. Le Guyon, K. Trillet +11
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. DNMT1-Mediated Epigenetic Reprogramming Drives KMT2A Amplifications and Rearrangements
    M. A. Lineberger, Z. H. Gray, B. I. Ferman +28
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{eldeiry2026case,
  title = {{Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR}},
  author = {Wafik S. El-Deiry and Sadakatsu Ikeda and Shai Magidi and Catherine Bresson and Hikmat Abdel-Razeq and Anthony Joshua and Alberto Hernando-Calvo and Arjun Oberoi and Zhihuang Hu and Tobias Meissner and Rachel Elsey and Amal Al-Omari and Fanny Wunder and Razelle Kurzrock},
  journal = {Oncotarget},
  year = {2026},
  month = oct,
  doi = {10.18632/oncotarget.28920},
  url = {https://doi.org/10.18632/oncotarget.28920},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR
AU  - Wafik S. El-Deiry
AU  - Sadakatsu Ikeda
AU  - Shai Magidi
AU  - Catherine Bresson
AU  - Hikmat Abdel-Razeq
AU  - Anthony Joshua
AU  - Alberto Hernando-Calvo
AU  - Arjun Oberoi
AU  - Zhihuang Hu
AU  - Tobias Meissner
AU  - Rachel Elsey
AU  - Amal Al-Omari
AU  - Fanny Wunder
AU  - Razelle Kurzrock
PY  - 2026
DA  - 2026/10/16
JO  - Oncotarget
DO  - 10.18632/oncotarget.28920
UR  - https://doi.org/10.18632/oncotarget.28920
AB  - The WIN Consortium International Molecular Tumor Board brings together precision oncology experts from 18 organizations in 13 countries across four continents and provides discussion for patients with cancer across the world. This case report details the medical journey of a 55-year-old man diagnosed with high-grade glioblastoma (GBM), characterized by amplifications of MDM2 and EGFR, alongside other critical genomic alterations, including a CDKN2A frameshift mutation. Despite the aggressive nature of GBM, the patient was in remission following a combination of radiotherapy and chemotherapy, surgery and participation in a phase II clinical trial (PI3K/mTOR inhibitor) combined with ketogenic diet and metformin. However, the patient was also considering personalized neoantigen vaccine therapy targeting tumor-specific mutated peptides as part of his treatment strategy.  This case underscores the immense complexity of treating GBM. Next generation sequencing showed MDM2 amplification, which hinders the tumor-suppressive functions of p53, and EGFR amplification, which promotes oncogenic signaling. The experts highlighted various therapeutic options discussed in the event of relapse: EGFR inhibitors, various MDM2 inhibitors, and personalized combination therapies targeting both EGFR and CDK4/6. Additionally, the Molecular Tumor Board discussed the reported risk of resistance or hyper-progression with immune checkpoint blockade in the presence of EGFR and MDM2 alterations. Innovative approaches such as combining MDM2 and EGFR inhibitors with immunotherapy, as well as the use of teserpaturev, a genetically engineered herpes simplex virus were addressed. This case emphasizes the importance of personalized treatment strategies for GBM and the need for ongoing clinical research to explore novel therapeutic options.
SN  - 1949-2553
ER  -